Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

620 ARTÍCULOS , VIENDO DEL 421 AL 435

Preclinical systematic review of ginsenoside Rg1 for cognitive impairment in Alzheimer's disease

Liang HY, Zhang PP, Zhang XL, Zheng YY, Huang YR, Zheng GQ, Lin Y.

Aging (Albany NY). 2021 Mar 3;13(5):7549-7569. doi: 10.18632/aging.202619. Epub 2021 Mar 3.

A Phase II, Single-Center, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Therapeutic Efficacy of Intranasal Glulisine in Amnestic Mild Cognitive Impairment and Probable Mild Alzheimer's Disease

Rosenbloom M, Barclay TR, Kashyap B, Hage L, O'Keefe LR, Svitak A, Pyle M, Frey W, Hanson LR.

Drugs Aging. 2021 May;38(5):407-415. doi: 10.1007/s40266-021-00845-7. Epub 2021 Mar 15.

Pathology, Risk Factors, and Oxidative Damage Related to Type 2 Diabetes-Mediated Alzheimer's Disease and the Rescuing Effects of the Potent Antioxidant Anthocyanin

Khan MS, Ikram M, Park TJ, Kim MO.

Oxid Med Cell Longev. 2021 Feb 27;2021:4051207. doi: 10.1155/2021/4051207. eCollection 2021.

Modifiable Risk Factors Associated with Alzheimer's Disease with Special Reference to Sleep Disturbance

Chauhan PS, Mishra M, Koul B, Sharma M, Yadav D.

CNS Neurol Disord Drug Targets. 2021;20(7):594-601. doi: 10.2174/1871527320666210319111852.

Reversal of cerebral hypoperfusion: a novel therapeutic target for the treatment of AD/ADRD?

Fan F, Roman RJ.

Geroscience. 2021 Apr;43(2):1065-1067. doi: 10.1007/s11357-021-00357-7. Epub 2021 Mar 27.

Commentary on "Cannabinoids for Agitation in Alzheimer's Disease"

Goveas JS.

Am J Geriatr Psychiatry. 2021 Dec;29(12):1264-1266. doi: 10.1016/j.jagp.2021.03.004. Epub 2021 Mar 19.

The effects of Huperzine A on dementia and mild cognitive impairment: An overview of systematic reviews

Ghassab-Abdollahi N, Mobasseri K, Dehghani Ahmadabad A, Nadrian H, Mirghafourvand M.

Phytother Res. 2021 Sep;35(9):4971-4987. doi: 10.1002/ptr.7126. Epub 2021 Apr 13.

Diet-Microbiota-Brain Axis in Alzheimer's Disease

Kincaid HJ, Nagpal R, Yadav H.

Ann Nutr Metab. 2021;77 Suppl 2(Suppl 2):21-27. doi: 10.1159/000515700. Epub 2021 Apr 27.

Anticholinergic drugs and the risk of dementia: A systematic review and meta-analysis

Zheng YB, Shi L, Zhu XM, Bao YP, Bai LJ, Li JQ, Liu JJ, Han Y, Shi J, Lu L.

Neurosci Biobehav Rev. 2021 Aug;127:296-306. doi: 10.1016/j.neubiorev.2021.04.031. Epub 2021 Apr 29.

Anticancer drugs repurposed for Alzheimer's disease: a systematic review

Ancidoni A, Bacigalupo I, Remoli G, Lacorte E, Piscopo P, Sarti G, Corbo M, Vanacore N, Canevelli M.

Alzheimers Res Ther. 2021 May 5;13(1):96. doi: 10.1186/s13195-021-00831-6.

Efficacy of preclinical pharmacological interventions against alterations of neuronal network oscillations in Alzheimer's disease: A systematic review

Isla AG, Balleza-Tapia H, Fisahn A.

Exp Neurol. 2021 Sep;343:113743. doi: 10.1016/j.expneurol.2021.113743. Epub 2021 May 14.

Sleep, Orexin and Cognition

Toor B, Ray LB, Pozzobon A, Fogel SM.

Front Neurol Neurosci. 2021;45:38-51. doi: 10.1159/000514960. Epub 2021 May 28.

Pharmacokinetic and pharmacodynamic evaluation of nasal liposome and nanoparticle based rivastigmine formulations in acute and chronic models of Alzheimer's disease

Rompicherla SKL, Arumugam K, Bojja SL, Kumar N, Rao CM.

Naunyn Schmiedebergs Arch Pharmacol. 2021 Aug;394(8):1737-1755. doi: 10.1007/s00210-021-02096-0. Epub 2021 Jun 4.

Effects of Folic Acid and Vitamin B12 Supplementation on Cognitive Impairment and Inflammation in Patients with Alzheimer's Disease: A Randomized, Single-Blinded, Placebo-Controlled Trial

Chen H, Liu S, Ge B, Zhou D, Li M, Li W, Ma F, Liu Z, Ji Y, Huang G.

J Prev Alzheimers Dis. 2021;8(3):249-256. doi: 10.14283/jpad.2021.22.

Genome-wide association identifies the first risk loci for psychosis in Alzheimer disease

DeMichele-Sweet MAA, Klei L, Creese B, Harwood JC, Weamer EA, McClain L, Sims R, Hernandez I, Moreno-Grau S, Tárraga L, Boada M, Alarcón-Martín E, Valero S; NIA-LOAD Family Based Study Consortium, Alzheimer’s Disease Genetics Consortium (ADGC); Liu Y, Hooli B, Aarsland D, Selbaek G, Bergh S, Rongve A, Saltvedt I, Skjellegrind HK, Engdahl B, Stordal E, Andreassen OA, Djurovic S, Athanasiu L, Seripa D, Borroni B, Albani D, Forloni G, Mecocci P, Serretti A, De Ronchi D, Politis A, Williams J, Mayeux R, Foroud T, Ruiz A, Ballard C, Holmans P, Lopez OL, Kamboh MI, Devlin B, Sweet RA.

Mol Psychiatry. 2021 Oct;26(10):5797-5811. doi: 10.1038/s41380-021-01152-8. Epub 2021 Jun 10.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias